MMP9 and glioblastoma: Bevacizumab (Bv), which targets on vascular endothelial growth factor (VEGF), a factor that recruits neutrophils expressing proangiogenic matrix metallopeptidase 9, is frequently used for glioblastoma (GBM) patients.